CHARM-offensief tegen hartfalen


1. White HD. Candesartan and heart failure: the allure of CHARM. Lancet 2003; 362: 754-755.
2. McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking ACE inhibitors: the CHARM-added trial. Lancet 2003; 362: 767-771.
3. Granger CB, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to ACE inhibitors: the CHARM-alternative Lancet 2003; 362: 772-776.
4. Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 2003; 362: 777-781.
5. Pfeffer MA, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003; 362: 759-766. 

Auteurs

  • dr A.J.F.A. Kerst